KK 8123
Alternative Names: KK-8123Latest Information Update: 11 Oct 2024
Price :
$50 *
At a glance
- Originator Kyowa Kirin
- Class Antibodies
- Mechanism of Action Fibroblast growth factor 23 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II X-linked dominant hypophosphataemic rickets
Most Recent Events
- 07 Oct 2024 Phase-I/II clinical trials in X-linked dominant hypophosphataemic rickets in USA (SC) (NCT06525636)
- 05 Aug 2024 Kyowa Kirin plans a phase I/II trial in X-linked dominant hypophosphataemic rickets (In adults) in USA, France, Germany and Spain (SC) in July 2024 (NCT06525636)
- 30 Jun 2024 Preclinical trials in X-linked dominant hypophosphataemic rickets in Japan (SC) prior to June 2024